Please assess the completion status of the following clinical trial:

Trial Title: A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Males and females, 18 to 89 years old, with type 2 diabetes with inadequate glycemic control HbA1c between 7-10.5% and uncontrolled hypertension Systolic Blood Pressure (SBP) 140-165 and Diastolic Blood Pressure (DBP) 85-105~* Subjects must have a mean 24 hr blood pressure ≥ 130/80 determined by Ambulatory Blood Pressure Monitoring (ABPM) within 1 week prior to Day 1 visit~* Stable dose of oral antidiabetic agent (OAD) for at least 6 weeks \[12 wks for Thiazolidinedione (TZD)\] or a stable daily dose of insulin, as a monotherapy or in combination with another OAD, for 8 weeks, and a stable dose of ACEI or ARB and 1 additional antihypertensive medication for at least 4 weeks~* C-peptide ≥ 0.8 ng/mL~* Body Mass Index ≤ 45.0 kg/m2~* Serum creatinine \< 1.50 mg/dL for men or \< 1.40 mg/dL for women~Exclusion Criteria:~* Aspartate aminotransferase (AST) and /or Alanine aminotransferase (ALT) \> 3.0\*upper limit of normal (ULN)~* Serum total bilirubin ≥ 1.5\*ULN~* Creatinine kinase \> 3\*ULN~* Symptoms of severely uncontrolled diabetes~* History of malignant or accelerated hypertension~* Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin 10 mg (Type: EXPERIMENTAL): Dapagliflozin 10 mg tablets
- Placebo matching Dapagliflozin (Type: PLACEBO_COMPARATOR): Placebo tablets matching dapagliflozin tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).